Pancreatic Cancer Research

ResearcherKagoshima UniversityNo recent work listed

Hiroyuki Shinchi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6207-2737; OpenAlex author ID A5072871817. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper

Papers 12

  1. Lung recurrence and its therapeutic strategy in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.015↗
  2. A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence. Co-author DOI 10.1097/mpa.0000000000001066↗
  3. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6357-1↗
  4. Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer. Co-author DOI 10.1007/s00268-016-3477-2↗
  5. CD133 Modulate HIF-1α Expression under Hypoxia in EMT Phenotype Pancreatic Cancer Stem-Like Cells. Co-author DOI 10.3390/ijms17071025↗
  6. [Radiotherapy for metastatic lesion of pancreatic cancer]. Co-author PMID 25857007↗
  7. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Soc… Co-author DOI 10.1002/jhbp.15↗
  8. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments:… Co-author DOI 10.1007/s00534-013-0616-0↗
  9. [Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy]. First author PMID 24393873↗
  10. Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer. Co-author DOI 10.1002/jso.23020↗
  11. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. Co-author DOI 10.1007/s00534-011-0400-y↗
  12. [A case of pancreatic cancer with liver metastasis controlled effectively by chemotherapy based on chemosensitivity test and stereotactic body radiotherapy]. First author PMID 22421785↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shoji Natsugoe · 10 shared papers, 2012–2020 · strength 0.55
  2. Kosei Maemura · 9 shared papers, 2012–2020 · strength 0.50
  3. Hiroshi Kurahara · 9 shared papers, 2012–2020 · strength 0.50
  4. Yuko Mataki · 9 shared papers, 2012–2020 · strength 0.50
  5. Sonshin Takao · 5 shared papers, 2012–2016 · strength 0.18
  6. Michiyo Higashi · 2 shared papers, 2013–2020 · strength 0.13
  7. Tetsuya Idichi · 1 shared paper, 2020 · strength 0.10
  8. Koki Maeda · 2 shared papers, 2012–2016 · strength 0.08
  9. Qiang Ding · 2 shared papers, 2012–2016 · strength 0.08
  10. Keita Wada · 2 shared papers, 2013–2014 · strength 0.06
  11. Sohei Satoi · 2 shared papers, 2013–2014 · strength 0.06
  12. Masayuki Sho · 2 shared papers, 2013–2014 · strength 0.06
  13. Hiroki Yamaue · 2 shared papers, 2013–2014 · strength 0.06
  14. Hiroaki Nagano · 2 shared papers, 2013–2014 · strength 0.06
  15. Koichiro Tsukasa · 1 shared paper, 2016 · strength 0.06
  16. Yumi Miyazaki · 1 shared paper, 2016 · strength 0.06
  17. Tomomi Hayashi · 1 shared paper, 2016 · strength 0.06
  18. Tomoo Kosuge · 1 shared paper, 2014 · strength 0.03
  19. Takaho Okada · 1 shared paper, 2014 · strength 0.03
  20. Yoshiaki Murakami · 1 shared paper, 2014 · strength 0.03
  21. Hideo Baba · 1 shared paper, 2014 · strength 0.03
  22. Minoru Kitago · 1 shared paper, 2014 · strength 0.03
  23. Tadahiro Takada · 1 shared paper, 2014 · strength 0.03
  24. Hidehiro Tajima · 1 shared paper, 2014 · strength 0.03
  25. Ippei Matsumoto · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.